Shares of Aridis Pharmaceuticals are dropping over 40% in late trading on Wednesday evening, to 71c per share, after closing the regular session up 46.4% to $1.23 per share, after reporting that the sample size of the study was limited and "lacked of statistical significance in the primary endpoint."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ARDS:
- Aridis Reports Top-Line Results of the Phase 3 Double-Blinded, Superiority Trial of AR-301 For the Treatment of Staphylococcus aureus Ventilator Associated Pneumonia (VAP)
- New Approaches to Treating Infections in Cystic Fibrosis Patients – AR 501 Phase 2 Trial Update
- Aridis to present AR 501 Phase 2 trial update for CF treatment at KOL
- Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
- (Updated) Aridis Pharmaceuticals Receives Equity Investment from the Cystic Fibrosis Foundation